Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma

Cancer Cell

Volumn 31, Issue 1, 2017, Pages 50-63

  Veschi, Veronica ^a   Liu, Zhihui ^a   Voss, Ty C ^a   Ozbun, Laurent ^a   Gryder, Berkley ^a   Yan, Chunhua ^a   Hu, Ying ^a   Ma, Anqi ^b   Jin, Jian ^b   Mazur, Sharlyn J ^a   Lam, Norris ^a   Souza, Barbara K ^a   Giannini, Giuseppe ^d   Hager, Gordon L ^a   Arrowsmith, Cheryl H ^c   Khan, Javed ^a   Appella, Ettore ^a   Thiele, Carol J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

differentiation; epigenetics; neuroblastoma; p53; SETD8; siRNA screen

Indexed keywords

ENZYME SETD8; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNC 0379; UNCLASSIFIED DRUG; 6,7-DIMETHOXY-2-(PYRROLIDIN-1-YL)-N-(5-(PYRROLIDIN-1-YL)PENTYL)QUINAZOLIN-4-AMINE; HISTONE LYSINE METHYLTRANSFERASE; QUINAZOLINE DERIVATIVE; SETD8 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIATION; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EPIGENETICS; EX VIVO STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN METHYLATION; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; CELL PROLIFERATION; EPIGENESIS, GENETIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; NEUROBLASTOMA; QUINAZOLINES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85009083867     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.12.002     Document Type: Article

References (47)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., Schapira, M., Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11 (2012), 384–400.
3. Bagatell, R., Beck-Popovic, M., London, W.B., Zhang, Y., Pearson, A.D., Matthay, K.K., Monclair, T., Ambros, P.F., Cohn, S.L., Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J. Clin. Oncol. 27 (2009), 365–370.
4. Balamuth, N.J., Wood, A., Wang, Q., Jagannathan, J., Mayes, P., Zhang, Z., Chen, Z., Rappaport, E., Courtright, J., Pawel, B., et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res. 70 (2010), 2749–2758.
5. Barbieri, E., De Preter, K., Capasso, M., Chen, Z., Hsu, D.M., Tonini, G.P., Lefever, S., Hicks, J., Versteeg, R., Pession, A., et al. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 74 (2014), 765–774.
6. Beck, D.B., Oda, H., Shen, S.S., Reinberg, D., PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev. 26 (2012), 325–337.
7. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
8. Blum, G., Ibanez, G., Rao, X., Shum, D., Radu, C., Djaballah, H., Rice, J.C., Luo, M., Small-molecule inhibitors of SETD8 with cellular activity. ACS Chem. Biol. 9 (2014), 2471–2478.
9. Bosse, K.R., Diskin, S.J., Cole, K.A., Wood, A.C., Schnepp, R.W., Norris, G., Nguyen le, B., Jagannathan, J., Laquaglia, M., Winter, C., et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 72 (2012), 2068–2078.
10. Canete, A., Gerrard, M., Rubie, H., Castel, V., Di Cataldo, A., Munzer, C., Ladenstein, R., Brichard, B., Bermudez, J.D., Couturier, J., et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol. 27 (2009), 1014–1019.
11. Cheung, N.K., Zhang, J., Lu, C., Parker, M., Bahrami, A., Tickoo, S.K., Heguy, A., Pappo, A.S., Federico, S., Dalton, J., et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307 (2012), 1062–1071.
12. Choi, Y.L., Kim, C.J., Matsuo, T., Gaetano, C., Falconi, R., Suh, Y.L., Kim, S.H., Shin, Y.K., Park, S.H., Chi, J.G., Thiele, C.J., HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J. Neurooncol. 73 (2005), 19–27.
13. Cui, H., Ma, J., Ding, J., Li, T., Alam, G., Ding, H.F., Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J. Biol. Chem. 281 (2006), 34696–34704.
14. Dhami, G.K., Liu, H., Galka, M., Voss, C., Wei, R., Muranko, K., Kaneko, T., Cregan, S.P., Li, L., Li, S.S., Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol. Cell 50 (2013), 565–576.
15. Frumm, S.M., Fan, Z.P., Ross, K.N., Duvall, J.R., Gupta, S., VerPlank, L., Suh, B.C., Holson, E., Wagner, F.F., Smith, W.B., et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem. Biol. 20 (2013), 713–725.
16. Garcia-Higuera, I., Manchado, E., Dubus, P., Canamero, M., Mendez, J., Moreno, S., Malumbres, M., Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 10 (2008), 802–811.
17. Hoebeeck, J., Michels, E., Pattyn, F., Combaret, V., Vermeulen, J., Yigit, N., Hoyoux, C., Laureys, G., De Paepe, A., Speleman, F., Vandesompele, J., Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 273 (2009), 336–346.
18. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128 (2007), 683–692.
19. Lawlor, E.R., Thiele, C.J., Epigenetic changes in pediatric solid tumors: promising new targets. Clin. Cancer Res. 18 (2012), 2768–2779.
20. Ma, A., Yu, W., Li, F., Bleich, R.M., Herold, J.M., Butler, K.V., Norris, J.L., Korboukh, V., Tripathy, A., Janzen, W.P., et al. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J. Med. Chem. 57 (2014), 6822–6833.
21. Ma, A., Yu, W., Xiong, Y., Butler, K.V., Brown, P.J., Jin, J., Structure-activity relationship studies of SETD8 inhibitors. MedChemComm 5 (2014), 1892–1898.
22. Maris, J.M., Recent advances in neuroblastoma. N. Engl. J. Med. 362 (2010), 2202–2211.
23. Molenaar, J.J., Koster, J., Zwijnenburg, D.A., van Sluis, P., Valentijn, L.J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B.A., van Arkel, J., et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483 (2012), 589–593.
24. Petroni, M., Veschi, V., Gulino, A., Giannini, G., Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma. Front Oncol., 2, 2012, 141.
25. Pugh, T.J., Morozova, O., Attiyeh, E.F., Asgharzadeh, S., Wei, J.S., Auclair, D., Carter, S.L., Cibulskis, K., Hanna, M., Kiezun, A., et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45 (2013), 279–284.
26. Puissant, A., Frumm, S.M., Alexe, G., Bassil, C.F., Qi, J., Chanthery, Y.H., Nekritz, E.A., Zeid, R., Gustafson, W.C., Greninger, P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3 (2013), 308–323.
27. Sausen, M., Leary, R.J., Jones, S., Wu, J., Reynolds, C.P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L.A. Jr., Papadopoulos, N., et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45 (2013), 12–17.
28. Schnepp, R.W., Khurana, P., Attiyeh, E.F., Raman, P., Chodosh, S.E., Oldridge, D.A., Gagliardi, M.E., Conkrite, K.L., Asgharzadeh, S., Seeger, R.C., et al. A LIN28B-RAN-AURKA signaling network promotes neuroblastoma tumorigenesis. Cancer Cell 28 (2015), 599–609.
29. Schulte, J.H., Eggert, A., Neuroblastoma. Crit. Rev. Oncogenesis 20 (2015), 245–270.
30. Schulte, J.H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, I., Pajtler, K., Klein-Hitpass, L., Kuhfittig-Kulle, S., et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69 (2009), 2065–2071.
31. Shi, X., Kachirskaia, I., Yamaguchi, H., West, L.E., Wen, H., Wang, E.W., Dutta, S., Appella, E., Gozani, O., Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27 (2007), 636–646.
32. Takawa, M., Cho, H.S., Hayami, S., Toyokawa, G., Kogure, M., Yamane, Y., Iwai, Y., Maejima, K., Ueda, K., Masuda, A., et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res. 72 (2012), 3217–3227.
33. Tweddle, D.A., Pearson, A.D., Haber, M., Norris, M.D., Xue, C., Flemming, C., Lunec, J., The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197 (2003), 93–98.
34. Van Maerken, T., Speleman, F., Vermeulen, J., Lambertz, I., De Clercq, S., De Smet, E., Yigit, N., Coppens, V., Philippe, J., De Paepe, A., et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 66 (2006), 9646–9655.
35. Van Maerken, T., Vandesompele, J., Rihani, A., De Paepe, A., Speleman, F., Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ. 16 (2009), 1563–1572.
36. Van Maerken, T., Rihani, A., Dreidax, D., De Clercq, S., Yigit, N., Marine, J.C., Westermann, F., De Paepe, A., Vandesompele, J., Speleman, F., Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol. Cancer Ther. 10 (2011), 983–993.
37. Veschi, V., Petroni, M., Bartolazzi, A., Altavista, P., Dominici, C., Capalbo, C., Boldrini, R., Castellano, A., McDowell, H.P., Pizer, B., et al. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. Cell Death Dis., 5, 2014, e1100.
38. Wang, K., Diskin, S.J., Zhang, H., Attiyeh, E.F., Winter, C., Hou, C., Schnepp, R.W., Diamond, M., Bosse, K., Mayes, P.A., et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469 (2011), 216–220.
39. Wang, C., Liu, Z., Woo, C.W., Li, Z., Wang, L., Wei, J.S., Marquez, V.E., Bates, S.E., Jin, Q., Khan, J., et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 72 (2012), 315–324.
40. Wang, Z., Dai, X., Zhong, J., Inuzuka, H., Wan, L., Li, X., Wang, L., Ye, X., Sun, L., Gao, D., et al. SCF(beta-TRCP) promotes cell growth by targeting PR-Set7/Set8 for degradation. Nat. Commun., 6, 2015, 10185.
41. Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Koellhoffer, E.C., Pomeroy, S.L., Orkin, S.H., Roberts, C.W., Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18 (2010), 316–328.
42. Wolf, M., Korja, M., Karhu, R., Edgren, H., Kilpinen, S., Ojala, K., Mousses, S., Kallioniemi, A., Haapasalo, H., Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer, 10, 2010, 181.
43. Wu, S., Rice, J.C., A new regulator of the cell cycle: the PR-Set7 histone methyltransferase. Cell Cycle 10 (2011), 68–72.
44. Wu, S., Wang, W., Kong, X., Congdon, L.M., Yokomori, K., Kirschner, M.W., Rice, J.C., Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 24 (2010), 2531–2542.
45. Yang, F., Sun, L., Li, Q., Han, X., Lei, L., Zhang, H., Shang, Y., SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31 (2012), 110–123.
46. Yang, J., AlTahan, A.M., Hu, D., Wang, Y., Cheng, P.H., Morton, C.L., Qu, C., Nathwani, A.C., Shohet, J.M., Fotsis, T., et al. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J. Natl. Cancer Inst., 107, 2015, djv080.
47. Zawacka-Pankau, J., Selivanova, G., Pharmacological reactivation of p53 as a strategy to treat cancer. J. Intern. Med. 277 (2015), 248–259.